Bioxcel Therapeutics Logo
Previous slide
Next slide

Latest News

VIEW ALL NEWS
Sep 04, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceVIEW RELEASE
Aug 27, 2025
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®VIEW RELEASE
Aug 26, 2025
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025VIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Sep 09, 2025 04:00 PM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

3.58

CHANGE

-0.65 (-15.37%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a registered trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

IGALMI is a registered trademark of BioXcel Therapeutics, Inc.
All other trademarks are the properties of their respective owners.
Copyright © 2025 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.